Your browser doesn't support javascript.
loading
The oncogenic fusion protein TAZ::CAMTA1 promotes genomic instability and senescence through hypertranscription.
Neil, Emily; Paredes, Roberto; Pooley, Oscar; Rubin, Brian; Kouskoff, Valerie.
Afiliação
  • Neil E; Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, M13 9PT, UK.
  • Paredes R; Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, M13 9PT, UK.
  • Pooley O; Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, M13 9PT, UK.
  • Rubin B; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA.
  • Kouskoff V; Developmental Hematopoiesis Group, Faculty of Biology, Medicine and Health, the University of Manchester, Manchester, M13 9PT, UK. valerie.kouskoff@manchester.ac.uk.
Commun Biol ; 6(1): 1174, 2023 11 18.
Article em En | MEDLINE | ID: mdl-37980390
ABSTRACT
TAZCAMTA1 is a fusion protein found in over 90% of Epithelioid Hemangioendothelioma (EHE), a rare vascular sarcoma with an unpredictable disease course. To date, how TAZCAMTA1 initiates tumour formation remains unexplained. To study the oncogenic mechanism leading to EHE initiation, we developed a model system whereby TAZCAMTA1 expression is induced by doxycycline in primary endothelial cells. Using this model, we establish that upon TAZCAMTA1 expression endothelial cells rapidly enter a hypertranscription state, triggering considerable DNA damage. As a result, TC-expressing cells become trapped in S phase. Additionally, TAZCAMTA1-expressing endothelial cells have impaired homologous recombination, as shown by reduced BRCA1 and RAD51 foci formation. Consequently, the DNA damage remains unrepaired and TAZCAMTA1-expressing cells enter senescence. Knockout of Cdkn2a, the most common secondary mutation found in EHE, allows senescence bypass and uncontrolled growth. Together, this provides a mechanistic explanation for the clinical course of EHE and offers novel insight into therapeutic options.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transativadores / Hemangioendotelioma Epitelioide Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transativadores / Hemangioendotelioma Epitelioide Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article